

What is claimed is:

1. A method for treating a CLEC16A-associated autoimmune disorder in a subject in need thereof, comprising administration of an effective amount of one or more agents selected from a mitophagy suppressor/modulator, an ER suppressor, a JAK2 inhibitor and SOCS1 inhibitor.
- 5 2. A method for treating CLEC16A-associated degeneration of the thymus, comprising administration of an agent that modulates expression of one or more of CD163, Bcl-2, Pax-5, V-cam1, CD8 and FoxP3, thereby altering the medulla cortex ratio in thymus and ameliorating symptoms associated with degeneration of the thymus.
3. A method for treating CLEC16A-associated degeneration of spleen comprising
10 administration of an agent that modulates one or more of CD163, CD68, Bcl-2, CD40, Pax5, Vcam1, CD3, and GzmB, thereby altering the white red pulp ratio in the spleen and ameliorating symptoms associated with degeneration of the spleen.
4. A method for treating CLEC16A-associated degeneration of the pancreas comprising administration of an agent which modulates CD163 expression and/or immune cell infiltration
15 and/or acini cell degeneration in the pancreas, thereby reducing autoimmune symptoms.
5. The method of any of claims 1 - 4 , wherein said CLEC16A associated autoimmune disorder is selected from type-1 diabetes, multiple sclerosis, primary adrenal insufficiency, Crohn's disease, primary biliary cirrhosis, juvenile idiopathic arthritis, rheumatoid arthritis, and alopecia areata, uveitis, neurodegeneration and lupus.
- 20 6. The method of any of claims 1 - 5, wherein said agents are rapamycin and tofacitinib.
7. The method of any of claims 1-5, wherein a nucleic acid from said subject is first assessed for an alteration in a CLEC16a encoding nucleic acid.